Prostate Biopsy Results Explained: Gleason Score, Grade Group, and What Happens Next

TL;DR

• A prostate biopsy can confirm whether prostate cancer is present and provide information about how the cells look under a microscope.
• The Gleason score combines the main cancer growth patterns identified in the biopsy. Modern scores usually range from 6 to 10.
• Grade Groups simplify Gleason scores into five categories, from Grade Group 1 to Grade Group 5.
• Gleason score alone does not determine what happens next. PSA, stage, MRI findings, biopsy extent, overall health, and personal priorities also matter.
• Experiences shared anonymously through the mama health app highlight common uncertainties around understanding results, treatment trade-offs, waiting for follow-up, and knowing which questions to bring to an appointment.

What does a prostate biopsy result tell you?

A prostate biopsy can show whether cancer is present and, if it is, provide information about its grade and extent within the sampled tissue.

A pathologist examines small pieces of prostate tissue under a microscope. The pathology report may include whether cancer was identified, the Gleason score, the Grade Group, how many biopsy cores contain cancer, how much cancer is present within individual cores, and which areas of the prostate contain cancer.

The biopsy is only one part of the overall assessment. PSA results, examination findings, MRI or other imaging, age, general health, and the extent of disease are considered alongside the pathology findings.

For a broader explanation of the condition itself, see mama health's overview of prostate cancer and how it is assessed.

What is a Gleason score?

The Gleason score describes the microscopic growth patterns of prostate cancer cells.

A pathologist identifies patterns within the cancer and assigns Gleason grades. In contemporary prostate cancer reporting, the relevant patterns are generally grades 3, 4, and 5.

Pattern 3 means the cancer glands remain relatively well formed.

Pattern 4 means gland structures are more irregular or poorly formed.

Pattern 5 means there is little or no recognizable gland formation.

Higher patterns indicate increasingly abnormal architecture and are associated with a greater likelihood of aggressive biological behaviour.

The Gleason score combines two patterns. A report may therefore say:

Gleason 3 + 4 = 7

The first number represents the predominant pattern in the sampled cancer. The second represents the next most important pattern used for scoring.

This is why 3 + 4 = 7 and 4 + 3 = 7 do not mean the same thing. In 4 + 3 disease, pattern 4 makes up a larger component.

For more detail, mama health also has a dedicated guide explaining how the two Gleason patterns are interpreted.

Why does Gleason 6 sound lower than it really is?

Gleason 6 is the lowest Gleason score normally assigned to prostate cancer on contemporary biopsy reporting, not the middle of a ten-point scale.

This can be confusing when someone first sees “6” on a report. It may look like six out of ten, but modern prostate cancer grading does not work that way.

A Gleason score of 3 + 3 = 6 corresponds to Grade Group 1, the lowest Grade Group.

At the other end of the spectrum, Gleason scores of 9 or 10 correspond to Grade Group 5.

What is a prostate cancer Grade Group?

The Grade Group system translates Gleason scores into five categories that are easier to interpret.

The contemporary ISUP Grade Group system provides a scale from Grade Group 1 to Grade Group 5.

Grade Group 1 corresponds to Gleason 3 + 3 = 6. This is the lowest Grade Group.

Grade Group 2 corresponds to Gleason 3 + 4 = 7. Pattern 3 is predominant, with some pattern 4.

Grade Group 3 corresponds to Gleason 4 + 3 = 7. Pattern 4 is predominant.

Grade Group 4 includes Gleason 4 + 4 = 8, 3 + 5 = 8, and 5 + 3 = 8.

Grade Group 5 includes Gleason 4 + 5 = 9, 5 + 4 = 9, and 5 + 5 = 10.

A higher Grade Group generally means the cells look more abnormal and are associated with a greater likelihood of aggressive behaviour.

However, Grade Group is not the same as cancer stage.

Grade describes how the cancer looks under the microscope. Stage describes where the cancer is located and whether it has spread.

You can read more about how prostate cancer stages describe the extent of disease.

What is the difference between Gleason 3+4 and 4+3?

Gleason 3+4 and Gleason 4+3 both total 7, but the predominant cancer pattern is different.

Gleason 3 + 4 = 7 is Grade Group 2. Most of the scored tumour has pattern 3 architecture, while a smaller component has pattern 4.

Gleason 4 + 3 = 7 is Grade Group 3. Pattern 4 is predominant.

That distinction matters because Grade Group 3 is generally associated with less favourable behaviour than Grade Group 2.

The total score is therefore not enough on its own. The order of the numbers matters.

What do positive biopsy cores mean?

Positive cores are biopsy samples in which cancer was identified.

A prostate biopsy takes tissue from different parts of the gland. A pathology report might describe several positive cores out of the total number obtained.

The report may also state the location of each positive core, the percentage or length of tissue containing cancer, the Gleason pattern within different samples, and whether different areas contain different Grade Groups.

The amount of cancer identified in biopsy samples can contribute to risk assessment, but more positive cores do not by themselves determine the stage or treatment approach.

A biopsy also samples selected areas rather than examining the entire prostate. Pathology findings therefore need to be interpreted together with imaging and the rest of the clinical picture.

What do terms such as perineural invasion or extraprostatic extension mean?

Additional pathology terms describe microscopic features that can add context to the main Gleason and Grade Group findings.

Perineural invasion means cancer cells are seen growing around or alongside a nerve within the sampled prostate tissue. Its significance depends on the wider clinical context. Finding perineural invasion does not, by itself, mean that cancer has spread to distant parts of the body.

Extraprostatic extension means cancer is identified extending beyond the normal boundary of the prostate. When identified, healthcare professionals consider it alongside imaging and other staging information.

A report may also mention features such as cribriform architecture or intraductal carcinoma. These findings can add important information to the pathology assessment and can be discussed with the urologist or oncology team.

Does the Grade Group tell you whether prostate cancer has spread?

No. Grade Group describes microscopic appearance, while staging assesses the extent of the cancer.

A high Grade Group can be associated with a greater likelihood of growth or spread, but it cannot show where the cancer is located.

Staging may incorporate information from physical examination, MRI, lymph-node assessment, PSMA PET/CT or other imaging when clinically appropriate, and other investigations selected for the individual situation.

The TNM system describes the primary tumour, regional lymph nodes, and distant metastases.

The distinction between grade and stage is important. Higher-grade disease can still be confined to the prostate. A biopsy result alone therefore cannot tell you whether prostate cancer has spread elsewhere.

For additional context, see the factors associated with how prostate cancer may progress over time.

How are biopsy results combined with PSA and stage?

Healthcare teams interpret the biopsy together with PSA, stage, imaging, and other clinical information to estimate risk and discuss appropriate options.

No single number determines the entire outlook.

Risk assessment may consider Grade Group, PSA level, clinical stage, MRI findings, the number and extent of positive biopsy cores, specific pathology features, age, general health, and the expected benefits and burdens of different approaches.

Current European guidance distinguishes different risk groups for localized and locally advanced prostate cancer. Intermediate-risk disease can also have more or less favourable characteristics.

This is one reason two people with the same Gleason score may have different discussions about what happens next.

What can happen after a Grade Group 1 biopsy result?

Active surveillance is a standard management approach for many people with low-risk Grade Group 1 prostate cancer when their wider clinical circumstances make it appropriate.

Active surveillance does not mean ignoring the cancer. It is an organized follow-up strategy intended to identify meaningful changes while avoiding or delaying treatment that may not be necessary.

The exact protocol varies. Follow-up can involve PSA testing, clinical review, MRI, and repeat biopsy according to the surveillance plan.

Grade Group 1 alone does not automatically establish that active surveillance is appropriate. PSA, stage, biopsy findings, imaging, general health, life expectancy, and other factors still matter.

Some carefully selected Grade Group 2 situations may also be considered for active surveillance when other characteristics are favourable. This requires an individualized discussion with the healthcare team.

What can happen after a Grade Group 2 or 3 result?

Grade Groups 2 and 3 require assessment of the complete risk profile before the available management options can be compared.

Depending on whether disease is localized and on other risk features, discussions can include active surveillance in selected favourable Grade Group 2 situations, radical prostatectomy, external-beam radiotherapy or other radiotherapy approaches, and watchful waiting when age, health, or life expectancy changes the balance of potential benefits and burdens.

It would be inaccurate to assume that every Gleason 7 result automatically requires surgery or radiotherapy.

The difference between Grade Groups 2 and 3 is also clinically relevant, as is the amount of pattern 4, PSA, stage, imaging findings, and the extent of cancer found in biopsy samples.

What can happen after a Grade Group 4 or 5 result?

Grade Groups 4 and 5 generally lead to further assessment of disease extent and a discussion of options appropriate to higher-risk disease.

What happens next depends strongly on whether the cancer is localized, locally advanced, or metastatic.

For localized or locally advanced higher-risk disease, discussions may involve combinations of local and systemic approaches. In metastatic disease, systemic therapies can play a central role, with the precise approach depending on disease characteristics, previous treatment, overall health, and current clinical guidance.

Importantly, a Grade Group 4 or 5 result does not, on its own, prove that the cancer has metastasized.

What do experiences shared through the mama health app reveal about receiving biopsy results?

Experiences shared anonymously through the mama health app highlight how understanding a biopsy report can be as challenging as receiving the numbers themselves.

One recurring theme is the gap between knowing a score and understanding what it means. Someone may remember “3+4” or “Grade Group 2” while still feeling uncertain about how that information relates to stage, longer-term outlook, or what may happen next.

Another theme is uncertainty after a lower-grade result. When active surveillance is discussed, some describe relief at avoiding immediate treatment alongside worry about living with a known cancer. Understanding what surveillance involves and why it is being considered can make that discussion easier to navigate.

Treatment trade-offs also feature prominently. When surgery or radiotherapy enters the discussion, concerns often move from the cancer itself to urinary, sexual, bowel, hormonal, and everyday-life effects. Some describe wanting clearer comparisons, more time to process the information, or another professional opinion before making a decision.

Waiting can be difficult as well. The period between biopsy, pathology results, staging investigations, and the next specialist appointment can create uncertainty, particularly when it is unclear what each result means or what the next appointment is intended to resolve.

These shared experiences cannot predict what will happen in an individual situation. They can, however, highlight questions and concerns that others have found useful to discuss with healthcare professionals.

You can also use mama health to make medical reports and lab results easier to understand in plain language, without unnecessary medical jargon. It can help explain unfamiliar terminology and organize information so you can reflect on it and prepare questions for your next appointment. It does not interpret results as a diagnosis or replace a healthcare professional's assessment.

This wording keeps mama health positioned as an informational and supportive resource rather than a diagnostic or clinical decision-making tool, in line with its intended-use guidance.

What questions could you bring to a biopsy-results appointment?

Writing down questions before the appointment can make a complex pathology discussion easier to follow.

Questions others have found useful include:

• What is my exact Gleason score?
• What is my Grade Group?
• What does the first number in my Gleason score represent?
• How many biopsy cores contained cancer?
• How much cancer was present in the positive cores?
• Were different Grade Groups found in different areas?
• Did the pathology report mention cribriform pattern, intraductal carcinoma, perineural invasion, or extraprostatic extension?
• What is my clinical stage?
• How do my PSA, MRI, biopsy findings, and stage fit together?
• Which risk group best describes my situation?
• Are any further scans or tests being considered?
• What management approaches could be discussed for this risk profile?
• What are the main potential benefits and side effects of each option?
• Is active surveillance relevant to my situation?
• Would a pathology review, multidisciplinary discussion, or second opinion add useful information?
• Is there a medically relevant timeframe for making a decision?

Not every question will apply to every biopsy report. A healthcare professional can explain which findings are most relevant in an individual case.

Can a biopsy Grade Group change later?

Yes. A later biopsy or surgical specimen can sometimes receive a different grade because a needle biopsy samples only part of the prostate.

A biopsy provides a sample rather than an examination of the entire gland.

If the prostate is later removed surgically, the pathologist can examine substantially more tissue. In some cases, the final surgical Grade Group is higher or lower than the biopsy Grade Group.

Repeat biopsies during active surveillance can also identify findings that differ from the original sample.

A change does not necessarily mean that the cancer suddenly changed at that moment. Differences in sampling can contribute.

Does a high Gleason score mean prostate cancer cannot be cured?

No. Gleason score is important, but it does not determine curability by itself.

Stage is particularly important because localized and metastatic disease are different clinical situations. PSA, Grade Group, overall health, tumour characteristics, and response to therapy can also influence outlook.

For more context, mama health explains how stage, grade, PSA, and other factors relate to the possibility of cure.

Individual prognosis should be discussed with the healthcare team familiar with the complete medical record.

What is the most important thing to understand about a prostate biopsy report?

The most important point is that the Gleason score is one part of a larger picture.

A biopsy report may initially look like a collection of unfamiliar numbers and pathology terms. Breaking them down makes the report easier to understand.

Gleason score describes the main microscopic patterns.

Grade Group translates those patterns into a scale from 1 to 5.

Biopsy extent describes where and how much cancer was found in the sampled tissue.

Stage describes the extent of the disease.

PSA and imaging provide additional information that healthcare professionals consider alongside the biopsy.

Experiences shared through the mama health app also show why it can be useful to leave a results appointment with more than a single score written down. Understanding the Grade Group, stage, risk assessment, possible next steps, and the reasons behind them can make future discussions easier to navigate.

If the terminology in a biopsy report, PSA result, or other lab report feels difficult to follow, mama health can help explain the information in simpler language and help you prepare questions to discuss with your doctor. The aim is to make complex health information easier to navigate, not to provide a diagnosis or make treatment decisions.

Disclaimer: This content is informational. mama health offers information and support and does not replace a doctor.